<DOC>
	<DOCNO>NCT01144832</DOCNO>
	<brief_summary>Purpose : To evaluate efficiency Irritable Bowel Syndrome ( IBS ) patient treatment H1-receptor antagonist ebastine . Design : Double blind randomized placebo control trial . IBS patient receive 12-weeks treatment ebastine 20mg daily placebo ( 1:1 randomization ) . End point : End point effect treatment clinical symptom visceral hypersensitivity evaluate barostat test .</brief_summary>
	<brief_title>Irritable Bowel Syndrome ( IBS ) Treatment With H1-receptor Antagonists</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Ebastine</mesh_term>
	<mesh_term>Histamine H1 Antagonists</mesh_term>
	<criteria>Irritable Bowel Syndrome ( ROME III criterion ) age 1865 year medication : antidepressant H1receptor antagonists pregnancy , breast feeding comorbidity : severe kidney and/or liver disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>visceral hypersensitivity</keyword>
	<keyword>mast cell</keyword>
</DOC>